• Email Alerts
  • Careers
  • Contact Us

SCYNEXIS, Inc.

  • Home
  • About Us
    • Overview
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Partnerships
    • Careers
    • Contact
  • Product
    • ibrexafungerp
    • Patent
  • Pipeline
    • Ibrexafungerp Development Pipeline
    • Clinical Trials
    • Vulvovaginal Candidiasis
    • Refractory Invasive Fungal Infections
    • Invasive Candidiasis
    • Invasive Aspergillosis
  • Science
    • SCYNEXIS Research Platform
    • Publications and Presentations
    • Expanded Access
  • News
    • Press Releases
    • Events
  • Investors
    • Overview
    • News Releases
    • Events & Presentations
    • Corporate Governance
    • Financials & Filings
    • Stock Data

SCYNEXIS, Inc.

You are now leaving the SCYNEXIS Corporate Website.

I understand Cancel

Press Releases

News

News

  • Press Releases
  • Events

SCYNEXIS Announces Pricing of $45 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants

Apr 22, 2022

SCYNEXIS Announces Positive Interim Data from Phase 3 FURI and CARES Studies Highlighting Oral Ibrexafungerp's Potency Against Severe Fungal Infections

Apr 22, 2022

SCYNEXIS Announces Launch of Public Offering of Common Stock and Warrants

Apr 21, 2022

SCYNEXIS to Present Positive Interim Data from Ongoing FURI and CARES Studies at the 32nd Annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) Being Held April 23-26 in Lisbon, Portugal

Apr 20, 2022

SCYNEXIS Secures Additional Commercial Insurance Formulary Coverage for BREXAFEMME® (ibrexafungerp tablets), Providing Access to an Estimated 93 Million Commercially-Insured Lives

Apr 19, 2022

SCYNEXIS to Participate in Upcoming April Women’s Health Medical Conferences

Apr 4, 2022

SCYNEXIS Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Mar 29, 2022

SCYNEXIS to Report Fourth Quarter and Full Year 2021 Financial Results and Provide a Business Update

Mar 24, 2022

SCYNEXIS Named to Fast Company’s 2022 List of the World’s Most Innovative Companies

Mar 8, 2022

SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 4, 2022
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...16

    1 Evertrust Plaza, Jersey City, NJ 07302
    (201) 884-5485
    View Google Map

    © 2022 SCYNEXIS, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap Contact Us